Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis.
Level 1 - systematic review of randomized trials
Systematic review and meta-analysis of randomized controlled trials
PubMed 39431379 · doi:10.1111/dom.16012
What was done
Systematic review and meta-analysis of randomized controlled trials identified from PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov (inception to October 2023). Studies evaluated GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists reporting body composition changes. Data were pooled using random-effects models as weighted mean differences (WMDs) with 95% confidence intervals (CIs).
What was found
Nineteen randomized controlled trials were included. Compared to controls, GLP-1 receptor-based agonists produced: - Reduction in fat body mass: WMD -2.25 kg (95% CI -3.40 to -1.10 kg) - Reduction in subcutaneous fat area: WMD -38.35 cm² (95% CI -54.75 to -21.95 cm²) - Reduction in visceral fat area: WMD -14.61 cm² (95% CI -23.77 to -5.44 cm²) - Reduction in lean body mass: WMD -1.02 kg (95% CI -1.46 to -0.57 kg) - Lean mass percentage changes were comparable between GLP-1 receptor-based agonist users and non-users (no specific numbers reported in the abstract).
Why it matters
This meta-analysis quantifies the concurrent loss of fat and lean tissue with GLP-1-based therapies, demonstrating that while absolute lean mass declines by approximately 1 kg, relative lean mass percentage is preserved.
Limits
The total number of randomized participants, specific drug agents/doses, treatment durations, and baseline patient characteristics (such as diabetes vs. obesity alone) are not reported in the abstract. Body composition measurement methods (e.g., DXA, MRI, BIA) and functional muscle outcomes (strength, physical performance) are not detailed.
Cited by
- supports GLP-1 medications do not inherently consume or break down muscle and bone tissue directly; any loss of lean mass is due to general weight loss.